Sentences with phrase «results in a timely manner»

We perform these lab services on - site so that patients receive results in a timely manner.

Parents complained that they were not made aware of the test results in a timely manner.

To provide feedback that helps students improve their learning, we must return the results in a timely manner.

Requires the district to notify a teacher of his / her appraisal results in a timely manner so that it can be used as a developmental tool by the district and teacher to improve performance.

For those instances where further diagnostic testing beyond what we are capable of performing in - house is deemed necessary, we have established long - term relationships with a number of outside laboratories, whom we are confident will provide accurate results in a timely manner.

Needing to quickly obtain the TROs, the firm required rapid - response document review services by a company that could deliver quality results in a timely manner.

Course sponsors are solely responsible for reporting results in a timely manner.

The goal is to maximize customer commitment and the prosperity of business by producing results in a timely manner.

Highly organized and articulate; able to achieve results in a timely manner.

Accurate, organized, and able to apply results in a timely manner.

We pride ourselves on delivering great results in a timely manner.

Our goal is to minimize any client system downtime and exceed customer expectations by ensuring quality results in a timely manner.

Created and executed test cases, wrote automated test scripts for new features and reported test results in a timely manner

We work one on one with our clients in conflict, to design and implement a specific working plan to produce results in a timely manner.

Not exact matches

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

«We believe if JPM can successfully resolve its regulatory and legal headline risk in a timely manner, the stock could reverse its recent underperformance that has resulted in trading at a below - peer forward (price to earnings ratio) of 8.8 times despite our expectations of above - average profitability in 2014,» Matthew Burnell, an analyst at Wells Fargo Securities, wrote in a research note Thursday following the fine.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

For example, the expected timing and likelihood of completion of the proposed merger, including the timing, receipt and terms and conditions of any required governmental and regulatory approvals of the proposed merger that could reduce anticipated benefits or cause the parties to abandon the transaction, the ability to successfully integrate the businesses, the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, the possibility that Kraft shareholders may not approve the merger agreement, the risk that the parties may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all, risks related to disruption of management time from ongoing business operations due to the proposed transaction, the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of Kraft's common stock, and the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Kraft and Heinz to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses generally, problems may arise in successfully integrating the businesses of the companies, which may result in the combined company not operating as effectively and efficiently as expected, the combined company may be unable to achieve cost - cutting synergies or it may take longer than expected to achieve those synergies, and other factors.

In addition to factors previously disclosed in Tesla's and SolarCity's reports filed with the U.S. Securities and Exchange Commission (the «SEC») and those identified elsewhere in this document, the following factors, among others, could cause actual results to differ materially from forward - looking statements and historical performance: the ability to obtain regulatory approvals and meet other closing conditions to the transaction, including requisite approval by Tesla and SolarCity stockholders, on a timely basis or at all; delay in closing the transaction; the ultimate outcome and results of integrating the operations of Tesla and SolarCity and the ultimate ability to realize synergies and other benefits; business disruption following the transaction; the availability and access, in general, of funds to meet debt obligations and to fund ongoing operations and necessary capital expenditures; and the ability to comply with all covenants in the indentures and credit facilities of Tesla and SolarCity, any violation of which, if not cured in a timely manner, could trigger a default of other obligations under cross-default provisionIn addition to factors previously disclosed in Tesla's and SolarCity's reports filed with the U.S. Securities and Exchange Commission (the «SEC») and those identified elsewhere in this document, the following factors, among others, could cause actual results to differ materially from forward - looking statements and historical performance: the ability to obtain regulatory approvals and meet other closing conditions to the transaction, including requisite approval by Tesla and SolarCity stockholders, on a timely basis or at all; delay in closing the transaction; the ultimate outcome and results of integrating the operations of Tesla and SolarCity and the ultimate ability to realize synergies and other benefits; business disruption following the transaction; the availability and access, in general, of funds to meet debt obligations and to fund ongoing operations and necessary capital expenditures; and the ability to comply with all covenants in the indentures and credit facilities of Tesla and SolarCity, any violation of which, if not cured in a timely manner, could trigger a default of other obligations under cross-default provisionin Tesla's and SolarCity's reports filed with the U.S. Securities and Exchange Commission (the «SEC») and those identified elsewhere in this document, the following factors, among others, could cause actual results to differ materially from forward - looking statements and historical performance: the ability to obtain regulatory approvals and meet other closing conditions to the transaction, including requisite approval by Tesla and SolarCity stockholders, on a timely basis or at all; delay in closing the transaction; the ultimate outcome and results of integrating the operations of Tesla and SolarCity and the ultimate ability to realize synergies and other benefits; business disruption following the transaction; the availability and access, in general, of funds to meet debt obligations and to fund ongoing operations and necessary capital expenditures; and the ability to comply with all covenants in the indentures and credit facilities of Tesla and SolarCity, any violation of which, if not cured in a timely manner, could trigger a default of other obligations under cross-default provisionin this document, the following factors, among others, could cause actual results to differ materially from forward - looking statements and historical performance: the ability to obtain regulatory approvals and meet other closing conditions to the transaction, including requisite approval by Tesla and SolarCity stockholders, on a timely basis or at all; delay in closing the transaction; the ultimate outcome and results of integrating the operations of Tesla and SolarCity and the ultimate ability to realize synergies and other benefits; business disruption following the transaction; the availability and access, in general, of funds to meet debt obligations and to fund ongoing operations and necessary capital expenditures; and the ability to comply with all covenants in the indentures and credit facilities of Tesla and SolarCity, any violation of which, if not cured in a timely manner, could trigger a default of other obligations under cross-default provisionin closing the transaction; the ultimate outcome and results of integrating the operations of Tesla and SolarCity and the ultimate ability to realize synergies and other benefits; business disruption following the transaction; the availability and access, in general, of funds to meet debt obligations and to fund ongoing operations and necessary capital expenditures; and the ability to comply with all covenants in the indentures and credit facilities of Tesla and SolarCity, any violation of which, if not cured in a timely manner, could trigger a default of other obligations under cross-default provisionin general, of funds to meet debt obligations and to fund ongoing operations and necessary capital expenditures; and the ability to comply with all covenants in the indentures and credit facilities of Tesla and SolarCity, any violation of which, if not cured in a timely manner, could trigger a default of other obligations under cross-default provisionin the indentures and credit facilities of Tesla and SolarCity, any violation of which, if not cured in a timely manner, could trigger a default of other obligations under cross-default provisionin a timely manner, could trigger a default of other obligations under cross-default provisions.

As a result of our ever - changing and evolving world, it has become necessary for firms in the financial services industry to take steps to ensure their preparedness to meet customer needs and resume regular business operations in a timely manner in the event of an SBD.

Announcement of auction results - The weighted average award rate and total amount lent for each issue will be released in a timely manner after the auction is complete.

Many factors could cause BlackBerry's actual results, performance or achievements to differ materially from those expressed or implied by the forward - looking statements, including, without limitation: BlackBerry's ability to enhance its current products and services, or develop new products and services in a timely manner or at competitive prices, including risks related to new product introductions; risks related to BlackBerry's ability to mitigate the impact of the anticipated decline in BlackBerry's infrastructure access fees on its consolidated revenue by developing an integrated services and software offering; intense competition, rapid change and significant strategic alliances within BlackBerry's industry; BlackBerry's reliance on carrier partners and distributors; risks associated with BlackBerry's foreign operations, including risks related to recent political and economic developments in Venezuela and the impact of foreign currency restrictions; risks relating to network disruptions and other business interruptions, including costs, potential liabilities, lost revenues and reputational damage associated with service interruptions; risks related to BlackBerry's ability to implement and to realize the anticipated benefits of its CORE program; BlackBerry's ability to maintain or increase its cash balance; security risks; BlackBerry's ability to attract and retain key personnel; risks related to intellectual property rights; BlackBerry's ability to expand and manage BlackBerry (R) World (TM); risks related to the collection, storage, transmission, use and disclosure of confidential and personal information;

Many factors could cause BlackBerry's actual results, performance or achievements to differ materially from those expressed or implied by the forward - looking statements, including, without limitation: BlackBerry's ability to enhance its current products and services, or develop new products and services in a timely manner or at competitive prices, including risks related to new product introductions; risks related to BlackBerry's ability to mitigate the impact of the anticipated decline in BlackBerry's infrastructure access fees on its consolidated revenue by developing an integrated services and software offering; intense competition, rapid change and significant strategic alliances within BlackBerry's industry; BlackBerry's reliance on carrier partners and distributors; risks associated with BlackBerry's foreign operations, including risks related to recent political and economic developments in Venezuela and the impact of foreign currency restrictions; risks relating to network disruptions and other business interruptions, including costs, potential liabilities, lost revenues and reputational damage associated with service interruptions; risks related to BlackBerry's ability to implement and to realize the anticipated benefits of its CORE program; BlackBerry's ability to maintain or increase its cash balance; security risks; BlackBerry's ability to attract and retain key personnel; risks related to intellectual property rights; BlackBerry's ability to expand and manage BlackBerry ® World ™; risks related to the collection, storage, transmission, use and disclosure of confidential and personal information; BlackBerry's ability to manage inventory and asset risk; BlackBerry's reliance on suppliers of functional components for its products and risks relating to its supply chain; BlackBerry's ability to obtain rights to use software or components supplied by third parties; BlackBerry's ability to successfully maintain and enhance its brand; risks related to government regulations, including regulations relating to encryption technology; BlackBerry's ability to continue to adapt to recent board and management changes and headcount reductions; reliance on strategic alliances with third - party network infrastructure developers, software platform vendors and service platform vendors; BlackBerry's reliance on third - party manufacturers; potential defects and vulnerabilities in BlackBerry's products; risks related to litigation, including litigation claims arising from BlackBerry's practice of providing forward - looking guidance; potential charges relating to the impairment of intangible assets recorded on BlackBerry's balance sheet; risks as a result of actions of activist shareholders; government regulation of wireless spectrum and radio frequencies; risks related to economic and geopolitical conditions; risks associated with acquisitions; foreign exchange risks; and difficulties in forecasting BlackBerry's financial results given the rapid technological changes, evolving industry standards, intense competition and short product life cycles that characterize the wireless communications industry.

As a result, we may not be able to secure additional financing in a timely manner, or at all, to meet our future capital needs, which may have an adverse effect on our business, operating results and financial condition.

As a result of our hard work and dedication to delivering to our customers consistently, reliably, and in a timely manner, we have created the world's largest and most efficient phytocannabinoid rich industrial hemp supply chain system.

Research grants should be awarded by a qualified, independent panel, and the research results should be made publicly available in a timely manner.

The Republican Caucus, led by Minority Leader John J. Mills, has grown continually frustrated by Legislators and opportunists who have attempted to ignore the will of the people and as a result hindered efforts to present a fair map in a timely manner that would allow interested candidates to become involved in the process.

We then made the results freely available to all — including Mars's competitors — over the Internet because we felt no single organization has the resources to, in a timely manner, do the breeding work needed to save the species from the various crises it faces.

To notice positive results all you need to do is respect the schedule for taking the supplement pack and youThe crazy bulk is the right supplement helps to build sufficient muscles in your body with very perfect manner just you need to follow the schedule for taking the supplement timely.

Sixty - seven percent of parents completely or somewhat agree that formative and interim assessment results are delivered in a timely manner (compared to 50 percent for summative results).

Studies on the design of state accountability systems should start with the needs of various constituencies and move to a determination of the extent to which timely, straightforward, and equitable results can be produced, and in what manner.

One of the participants shared that she «really appreciated that the «assignments» were open - ended enough that [she] could apply [the results] to [her] own work», and another participant commented, «This [course] was so much better than any other (M) OOC I've ever participated in before... With this course, I felt like I had the autonomy to proceed at my own pace while still being able to interact with other course members in meaningful ways (e.g. getting constructive criticism / feedback on my assignments in a timely manner, seeing what other people created, etc.)».

Various education matters, including requiring ISTEP + results are delivered in a timely manner and amending disability categories.

Through a collaborative evaluation process and immediate access to results, actionable feedback is able to be delivered in a timely manner.

The single - school configuration helped the teachers easily administer common assessments, obtain assessment data from a larger sample size (3 biology classrooms), and use the information from their collaborative study of the assessments results to modify instruction in a timely manner.

But, while results available last year were returned in a timely manner, the same could not be accomplished this year.

With Connecticut's State Department of Education refusing to release the results of the 2015 Common Core Smarter Balanced Assessment Consortium (SBAC) in a timely manner — other states released their state wide results at least six weeks ago — Madison, Connecticut Superintendent Thomas Scarice speaks the truth about the unfair, inappropriate and discriminatory SBAC testing scam.

These decisions need to be informed by data that is gathered as a result of efficient assessments and progress monitoring that are accomplished in a regular and timely manner.

(d) You must transmit test results to the MRO in a timely manner, preferably the same day that review by the certifying scientist is completed.

WASHINGTON — The U.S. Department of Transportation's National Highway Traffic Safety Administration (NHTSA) today announced that Hyundai has agreed to pay a $ 17.35 million civil penalty and comply with NHTSA oversight requirements outlined in a Consent Order as a result of the manufacturer failing to report in a timely manner a safety - related defect affecting 2009 - 2012 Hyundai Genesis vehicles.

Toyota later paid nearly $ 33 million in civil penalties as the result of investigations into whether the company notified NHTSA in a timely manner about these defects.

December 20, 2010: Toyota agrees to pay the maximum $ 16.375 million civil penalty as the result of another NHTSA investigation into whether their recall of 5.5 million vehicles for pedal entrapment was conducted in a timely manner.

Richard turned up right on time as scheduled, and completed the repair in a timely and professional manner, even «fixing» the error messages in the computer that had resulted from the initial problem.

That professional will prepare an exceptional literature review, assist with development of research methodologies, summarize the results of experiments, analyze data, and produce an original lab report in a timely manner.

Thus, you get the best result - essay written in full accordance to your requirements, delivered in timely manner, and containing only relevant data!

Credit card debt results when the funds are not repaid in a timely manner.

Failure to repay overdrafts in a timely manner will result in account closure.

Not this time Vitesse Financial delivers what they promises and in a very timely manner... All my clients with glitches on there reports — 1st stop Vitesse Financial — the savings on their new loans SUBSTANTIAL!!!!! (Your results will vary)

Cleaning up your credit will be the result of improved financial habits like paying your monthly bills in a timely manner and making more than the minimum payments.

Judy Kishner, President of SPAY OK, said, «In addition to the health benefits of spaying pets before sexual maturity, the failure to spay a pet in a timely manner results in euthanasias, animal abandonment, wasted shelter resources and morIn addition to the health benefits of spaying pets before sexual maturity, the failure to spay a pet in a timely manner results in euthanasias, animal abandonment, wasted shelter resources and morin a timely manner results in euthanasias, animal abandonment, wasted shelter resources and morin euthanasias, animal abandonment, wasted shelter resources and more.